<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Oncol Lett</journal-id><journal-id journal-id-type="iso-abbrev">Oncol Lett</journal-id><journal-id journal-id-type="publisher-id">OL</journal-id><journal-title-group><journal-title>Oncology Letters</journal-title></journal-title-group><issn pub-type="ppub">1792-1074</issn><issn pub-type="epub">1792-1082</issn><publisher><publisher-name>D.A. Spandidos</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">23420582</article-id><article-id pub-id-type="pmc">3572991</article-id><article-id pub-id-type="doi">10.3892/ol.2012.1022</article-id><article-id pub-id-type="publisher-id">ol-05-02-0463</article-id><article-categories><subj-group subj-group-type="heading"><subject>Articles</subject></subj-group></article-categories><title-group><article-title>Effects of different sequences of pulmonary artery and vein ligations during pulmonary lobectomy on blood micrometastasis of non-small cell lung cancer</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>SONG</surname><given-names>PING-PING</given-names></name><xref ref-type="aff" rid="af1-ol-05-02-0463"><sup>1</sup></xref><xref ref-type="aff" rid="af2-ol-05-02-0463"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>ZHANG</surname><given-names>WEIDI</given-names></name><xref ref-type="aff" rid="af2-ol-05-02-0463"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>ZHANG</surname><given-names>BAIJIANG</given-names></name><xref ref-type="aff" rid="af2-ol-05-02-0463"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>LIU</surname><given-names>QI</given-names></name><xref ref-type="corresp" rid="c1-ol-05-02-0463"/><xref ref-type="aff" rid="af1-ol-05-02-0463"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>DU</surname><given-names>JIAJUN</given-names></name><xref ref-type="corresp" rid="c1-ol-05-02-0463"/><xref ref-type="aff" rid="af1-ol-05-02-0463"><sup>1</sup></xref></contrib></contrib-group><aff id="af1-ol-05-02-0463"><label>1</label>Institute of Oncology, Provincial Hospital Affiliated to Shandong University, Shandong University, Jinan 250021;</aff><aff id="af2-ol-05-02-0463"><label>2</label>Department of Thoracic Surgery, Shandong Tumor Hospital, Jinan 250117, 
<country>P.R. China</country></aff><author-notes><corresp id="c1-ol-05-02-0463">Correspondence to: Professor Jia-Jun Du or Professor Qi Liu, Institute of Oncology, Provincial Hospital Affiliated to Shandong University, Shandong University, 324 Jingwu Road, Jinan 250021, P.R. China, E-mail: <email>dujiajun@sdu.edu.cn</email>, E-mail: <email>liuqi66@sdu.edu.cn</email></corresp></author-notes><pub-date pub-type="ppub"><month>2</month><year>2013</year></pub-date><pub-date pub-type="epub"><day>09</day><month>11</month><year>2012</year></pub-date><pub-date pub-type="pmc-release"><day>09</day><month>11</month><year>2012</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on the
							<pub-date pub-type="epub"/>. --><volume>5</volume><issue>2</issue><fpage>463</fpage><lpage>468</lpage><history><date date-type="received"><day>02</day><month>7</month><year>2012</year></date><date date-type="accepted"><day>01</day><month>10</month><year>2012</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2013, Spandidos Publications</copyright-statement><copyright-year>2013</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/3.0"><license-p>This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited.</license-p></license></permissions><abstract><p>The aim of this study was to investigate the effects of different sequences of pulmonary artery and vein ligations during lobectomy on blood micrometastasis of non-small cell lung cancer (NSCLC). Cytokeratin 19 (CK19)/adhesion molecule CD44v6 mRNA were used as markers. A total of 30 NSCLC patients undergoing pulmonary lobectomy were randomly divided into pulmonary artery (PA)-first and pulmonary vein (PV)-first groups according to the order of artery or vein ligation (15 cases in each). Fluorescent quantitative-RT-PCR (FQ-RT-PCR) was used to detect the mRNA expression of CK19 and CD44v6 in pulmonary venous blood at the early and late periods during surgery, and &#x00394;Ct values were calculated. Meanwhile, the peripheral blood samples from 10 healthy volunteers were selected as the control. &#x00394;Ct values of CD44v6 and CK19 of NSCLC groups at the early period during surgery were 7.83&#x000b1;1.70 and 10.76&#x000b1;2.74, while those of the control group were 9.17&#x000b1;1.04 and 12.76&#x000b1;2.36. The expression of CD44v6 and CK19 genes in venous blood of NSCLC groups was significantly higher than that of the control group (P&#x0003c;0.05). In addition, the &#x00394;Ct values of CD44v6 and CK19 in the early and late periods during surgery in the PA-first group were 7.92&#x000b1;1.97 vs. 5.67&#x000b1;2.11 (P= 0.008) and 11.21&#x000b1;3.14 vs. 8.60&#x000b1;4.02 (P= 0.05), respectively. The expression of CD44v6 and CK19 in the late period were both significantly higher than those in the early period, while neither the &#x00394;Ct value of CD44v6 nor that of CK19 in the early vs. late periods in the PV-first group exhibited statistically significant differences (7.95&#x000b1;1.91 vs. 7.74&#x000b1;2.10 and 10.60&#x000b1;3.15 vs. 10.30&#x000b1;2.98) (P&#x0003c;0.05). Surgical manipulation itself may stimulate the occurrence of blood micrometastasis and the ligation of the PV first during surgery may help prevent blood micrometastasis.</p></abstract><kwd-group><kwd>lung cancer</kwd><kwd>blood</kwd><kwd>micrometastasis</kwd></kwd-group></article-meta></front><body><sec><title>Introduction</title><p>Circulating tumor cells (CTCs) are present in the blood of patients with malignant tumors and are strongly correlated with the prognosis of patients. CTCs are formed when certain tumor cells escape from the solid tumor cell nests and gain access to the blood circulation. Thus, it is likely that any touching or crushing of the tumor during surgery may initiate this process. The issue of whether surgical manipulation of pulmonary lobectomy promotes blood micrometastasis, and whether different sequences of pulmonary artery (PA) and vein (PV) ligations have different effects on blood micrometastasis of pulmonary carcinoma remain controversial. Kurusu <italic>et al</italic> observed the mRNA expression of carcino-embryonic antigen (CEA) in the blood at early, middle and late periods during surgery and concluded that surgery could promote blood micrometastasis (<xref rid="b1-ol-05-02-0463" ref-type="bibr">1</xref>). Conversely, Refaely concluded that different sequences of PA and PV ligations bore no correlation with the prognosis of the patients (<xref rid="b2-ol-05-02-0463" ref-type="bibr">2</xref>). However, in the previous studies, the comparisons of related gene expression were made between those in the pulmonary venous blood during surgery and those in the peripheral blood before and after surgery, and thus certain errors may have been caused due to different blood samples. Therefore, to clarify the investigation of whether different sequences of PA and PV ligations have different effects on blood micrometastasis, errors caused by different blood samples should be avoided by making a comparison between gene expression in pulmonary venous blood at early and late periods during surgery (<xref rid="b3-ol-05-02-0463" ref-type="bibr">3</xref>). Thus, to perform a rigorous comparison, blood samples at early and late periods during surgery should both be drawn from the PV.</p><p>In this study, we aimed to assess whether the process of surgical manipulation itself affects blood micrometastasis. We randomly divided 30 patients suffering from non-small cell lung cancer (NSCLC) into PA-first and PV-first groups. Fluorescent quantitative-RT-PCR (FQ-RT-PCR) was used to detect the mRNA expression of CK19 and CD44v6 in the pulmonary venous blood at early and late periods during each operation.</p></sec><sec sec-type="materials|methods"><title>Materials and methods</title><sec><title>Patients</title><p>From January 2009 to January 2010, a total of 30 NSCLC patients underwent lobectomy for NSCLC in the thoracic surgery department of Shandong Tumor Hospital, China. The post-operative pathologic tumor-node-metastases (TNM) stage was determined according to the grading criteria of UICC. The diagnosis of lung cancer was histologically confirmed on each resected specimen where the tumor size was measured. Eligible patients had no history of previous anticancer therapy (including radiotherapy and chemotherapy) or other malignancy. The 10 cases in the control group were healthy volunteers with no history of malignancy. The study was approved by the ethics committee of Shandong Cancer Hospital and Institute, Jinan, China. Written informed patient consent was obtained from the patient&#x02019;s family with warrant of attorney.</p></sec><sec><title>Blood samples</title><p>All NSCLC patients were randomly divided into two groups: PV-first (15 cases) and PA-first (15 cases). For the PV-first group, the PV was separated following anesthesia and opening of the chest, 10 ml blood was drawn from the proximal part and then the vein was immediately ligated (but not cut off) at the distal part. Then, routine operative procedures were performed. After 30 min, another 10 ml blood was drawn from the proximal part of the PV (as distant from the ligated spot as possible) and then the vein was cut off. For the PA-first group, the PV was separated following anesthesia and opening of the chest, 10 ml blood was drawn from the proximal part and soon afterwards the ligation of the PA was carried out. After 20&#x02013;45 min, 10 ml blood was drawn from the proximal part of the vein. All patients underwent routine mediastinal lymphadenectomy following pulmonary lobectomy and recovered well after the operation. Peripheral vein blood samples were drawn from the controls. All blood samples were added into EDTA anticoagulation tubes and blood monocytes were obtained by Ficoll density gradient centrifugation, rinsing with PBS and centrifuging twice. Then, they were dissolved by adding 1 ml TRIzol reagent for the extraction of total RNAs.</p></sec><sec><title>Extraction of total RNAs</title><p>Total RNAs were extracted by adding 0.25 ml TRIzol&#x02122; reagent to Ficoll-isolated cells, mixing thoroughly and maintaing at room temperature for 5 min. Then, the homogenate was transferred into a 1.5 ml EP tube to which 0.05 ml choloroform was added, shaken vigorously for 15 sec and then maintained at room temperature for 2&#x02013;3 min. This was centrifuged at 10,000 &#x000d7; g for 15 min at 2&#x02013;8&#x000b0;C. The upper aqueous phase in the EP tube was transferred into a fresh tube, to which 0.125 ml isopropanol was added, and then maintained at room temperature for 10 min. This was centrifuged at 10,000 &#x000d7; g for 10 min at 2&#x02013;8&#x000b0;C. Supernatants were discarded. RNA precipitate was washed twice with 0.5 ml 75% ethanol, centrifuged at 7,500 &#x000d7; g for 5 min at 2&#x02013;8&#x000b0;C, dehumidified in air and then dissolved by adding RNase-free H<sub>2</sub>O. The absorbance of 260 nm (A260) was measured by nucleoprotein quantitative analyzer and the ratio of A260/A280 was used to measure RNA purity (the ratios were 1.8/2.0 in this study). All the samples were preserved at &#x02212;80&#x000b0;C.</p></sec><sec><title>Real-time PCR</title><p>RT reaction was carried out using PrimeScript&#x02122; RT kit (Perfect Real Time, Applied Biosystems, Carlsbad, CA, USA). The reaction system (10 <italic>&#x003bc;</italic>l) contained 2 <italic>&#x003bc;</italic>l 5X PrimeScript Buffer, 0.5 <italic>&#x003bc;</italic>l PrimeScript RT Enzyme Mix I, 0.5 <italic>&#x003bc;</italic>l Oligo dT Primer (50 <italic>&#x003bc;</italic>M), 0.5 <italic>&#x003bc;</italic>l random 6 primer (100 <italic>&#x003bc;</italic>M) and 1 <italic>&#x003bc;</italic>g RNA. The reaction conditions were 37&#x000b0;C for 15 min, followed by 85&#x000b0;C for 5 sec. Subsequently, cDNA samples were preserved in a &#x02212;80&#x000b0;C refrigerator.</p><p>SYBR<sup>&#x000ae;</sup> Premix Ex Taq&#x02122; (Perfect Real Time) kit was used for real-time PCR. A quantitative PCR system (25 <italic>&#x003bc;</italic>l) contained 12.5 <italic>&#x003bc;</italic>l 2X SYBR Premix Ex Taq, 0.5 <italic>&#x003bc;</italic>l forward primer (10 <italic>&#x003bc;</italic>M), 0.5 <italic>&#x003bc;</italic>l reverse primer (10 <italic>&#x003bc;</italic>M) and 100 ng cDNA. The primer sequences of CD44v6 were 5&#x02032;-AGCAACCCTACTGATGATGACG-3 (forward) and 5&#x02032;-GGAGTCTTCTCTGGGTGTTTGG-3 (reverse), and those of CK19 were 5&#x02032;-CTTCCGAACCAAGTTTGAGACG-3 (forward) and 5&#x02032;-CCTCAGCGTACTGATTTCCTCCT-3 (reverse). An ABI PRISM 7700 system was used for PCR. The amplification conditions were a cycle of pre-denaturation at 95&#x000b0;C for 30 sec, 40 cycles of 95&#x000b0;C for 5 sec and 60&#x000b0;C for 30 sec. &#x003b2;-actin was used as an internal standard. All the samples were repeated three times and the values of &#x00394;Ct were calculated. The Ct value was calculated by determining the point at which the fluorescence exceeded an arbitrary threshold limit. The value of &#x00394;Ct was obtained from the formula: Ct = Ct (target gene) &#x02212; Ct (&#x003b2;-actin). A higher &#x00394;Ct value indicated a lower target gene content and gene expression was lower with more amplification. Conversely, a lower &#x00394;Ct value indicated a greater target gene content and gene expression was higher with less amplification.</p></sec><sec><title>Statistical analysis</title><p>The Ct data of the genes were analyzed by SDS software (ABI). All the data were analyzed by SPSS 11.5 software. Student&#x02019;s t test was used. Differences were considered significant when P&#x0003c;0.05.</p></sec></sec><sec sec-type="results"><title>Results</title><sec><title>mRNA expression of CD44v6 and CK19</title><p>Fluorescent quantitative PCR was used to detect the mRNA expression of CK19 and CD44v6 in the pulmonary venous blood before and after venous ligation. For each reaction tube, the fluorescence signal of the reporter dye (FAM) was divided by the fluorescence signal of the passive reference dye (ROX), to obtain a ratio defined as the normalized reporter signal (Rn). DRn represents the normalized reporter signal (Rn) minus the baseline signal. The results indicated that &#x00394;Ct values of CD44v6 and CK19 of NSCLC groups at the early period during surgery were 7.83&#x000b1;1.70 vs. 10.76&#x000b1;2.74, respectively, while those of the control group were 9.17&#x000b1;1.04 vs. 12.76&#x000b1;2.36. The mRNA expression of CD44v6 and CK19 in NSCLC groups was significantly higher than that of the control group (P&#x0003c;0.05) (<xref rid="t1-ol-05-02-0463" ref-type="table">Table I</xref>, <xref rid="f1-ol-05-02-0463" ref-type="fig">Figs. 1</xref>&#x02013;<xref rid="f3-ol-05-02-0463" ref-type="fig">3</xref>).</p></sec><sec><title>Patient characteristics and the expression of CD44v6 and CK19</title><p>There was a clear difference in CD44v6 mRNA level between squamous cell carcinoma and adenocarcinoma at late periods during surgery (7.95&#x000b1;1.81 vs. 5.81&#x000b1;2.23; P=0.008). No significant correlation was identified between the expression of CD44v6 and CK19 and any other clinicopathological characteristics, at early and late periods during surgery (<xref rid="t2-ol-05-02-0463" ref-type="table">Table II</xref>).</p></sec><sec><title>Effects of different ligation sequences on the expression of CD44v6 and CK19</title><p>In the PA-first group, &#x00394;Ct values of CD44v6 and CK19 at early vs. late periods during surgery were 7.92&#x000b1;1.97 vs. 5.67&#x000b1;2.11 (P= 0.008) and 11.21&#x000b1;3.14 vs. 8.60&#x000b1;4.02 (P= 0.05), respectively. Both CD44v6 and CK19 values in the late period were significantly higher than those in the early period (P&#x02264;0.05). In the PV-first group, &#x00394;Ct values of CD44v6 and CK19 before and after ligation were 7.74&#x000b1;2.10 vs. 7.95&#x000b1;1.91, and 10.30&#x000b1;2.98 vs. 10.60&#x000b1;3.15, and &#x00394;Ct values of CD44v6 and CK19 before vs. after ligation were similar, exhibiting no statistically significant differences (P&#x0003e;0.05; <xref rid="t3-ol-05-02-0463" ref-type="table">Table III</xref>). The results indicated that mRNA expression of CD44v6 and CK19 in the PA-first group in the late period during surgery was significantly higher than that in the early period.</p></sec></sec><sec sec-type="discussion"><title>Discussion</title><p>The basic principles for tumor surgery advise that all procedures should be performed gently and any touching or crushing of the tumor should be minimized to reduce (or even avoid) the possibility that tumor cells may escape from the solid tumor cell nests and enter the circulation, thus causing blood micrometastasis. According to Turnbull <italic>et al</italic> and Hayashi <italic>et al</italic>(<xref rid="b5-ol-05-02-0463" ref-type="bibr">5</xref>,<xref rid="b6-ol-05-02-0463" ref-type="bibr">6</xref>), the application of a non-contact technique in colon carcinoma operations could reduce the formation of CTCs and improve the survival rate of patients. It was highly recommended that surgeons treat the tumor gently and avoid turning over and squeezing the mass as much as possible.</p><p>There has been emerging evidence to suggest that CK19 mRNA detection is strongly associated with the presence of lung cancer metastases or recurrence, particularly after surgery (<xref rid="b6-ol-05-02-0463" ref-type="bibr">6</xref>). CD44v6, the v6 variant of CD44, is mainly expressed in a subset of adenocarcinomas and the expression of adhesion molecule CD44v6 could well reflect the invasiveness and adhesiveness of malignant tumor cells. In this study, NSCLC patients were randomly divided into PA-first and PV-first groups, and blood samples from the early and late periods during surgery were both drawn from the vein in order to make an objective comparison between the effect of either PA or PV first. According to traditional theories, it is clearly required that ligation of the PV should be performed prior to that of the PA during lobectomy, to prevent the occurrence of CTCs entering the systemic circulation via pulmonary venous blood. No significant differences were identified between the expression of CD44v6 and CK19 in PV-first group at early and late periods during surgery, while significant differences were revealed in the PA-first group with a higher expression of CD44v6 and CK19 in the early period. It suggested that the operative procedures may play a promoting role in CTCs shedding off from the primary tumor and ingressing into the pulmonary venous blood, and that ligation of the PV first during surgery may help prevent the dissemination of CTCs. Ge <italic>et al</italic> detected the pre-, intra- and post-operative mRNA expression of CK19/CEA in peripheral venous blood of 23 NSCLC patients using fluorescent quantitative PCR (<xref rid="b7-ol-05-02-0463" ref-type="bibr">7</xref>). All patients were divided into either PV-first or PA-first groups at random. Results revealed that the intraoperative mRNA expression of CK19 was significantly higher than the pre- or post-operative expression (P&#x0003c;0.05); the highest mRNA expression of CEA was identified after surgery (P&#x0003c;0.05) and the ratio of CK19/CEA in the PA-first group was higher than that in the PV-first group (but without statistical significance). Yamashita also revealed that video-assisted thoracoscopic surgery (VATS) lobectomy was associated with a higher risk of seeding of tumor cells into the circulation during operation (<xref rid="b8-ol-05-02-0463" ref-type="bibr">8</xref>). Based on these results, it appears that surgical manipulation is capable of promoting the release of tumor cells into the bloodstream, and ligation of the PV prior to ligation of the PA may partly prevent such release during surgery.</p><p>Although numerous studies appear to support the opinion that the PV should be ligated prior to the PA during surgical intervention and that this order of vessel ligation may improve the prognosis of patients with NSCLC, there are still various opinions. According to Refaely <italic>et al</italic>, different sequences of PA and vein ligations bore no correlation with tumor recurrence and prognosis (<xref rid="b2-ol-05-02-0463" ref-type="bibr">2</xref>). In the study, a total of 279 NSCLC patients were randomly divided into PV-first (133 patients, 48%) and PA-first (146 patients, 52%) groups. The follow-up results revealed that the total recurrence rates in the two groups were similar and multivariate analysis (controlling for the effect of the performing surgeon) revealed that sequence of vessel interruption was not a risk factor. The results revealed that the sequence of vessel interruption during lobectomy did not play a role in tumor recurrence.</p><p>It is conceivable that most of the cancer cells shed into the blood stream during surgery are ultimately likely be destroyed by natural defense mechanisms, and extremely few of the tumor cells succeed in establishing secondary tumors. As the content of tumor cells in the blood circulation was extremely low, the sensitivity and specificity of detection is commonly required so that even one tumor cell can be detected in 10<sup>5</sup>&#x02013;10<sup>7</sup> cells. At present, the detection methods for tumor micrometastasis include immunohistochemistry, flow cytometry and RT-PCR, among which RT-PCR has been well accepted by virtue of its high sensitivity and specificity in detecting one tumor cell among 10<sup>5</sup>&#x02013;10<sup>7</sup> cells (<xref rid="b9-ol-05-02-0463" ref-type="bibr">9</xref>,<xref rid="b10-ol-05-02-0463" ref-type="bibr">10</xref>).</p><p>Numerous studies confirmed that the detection of CTCs in peripheral blood was associated with poor prognosis of the patient. Using RT-PCR, Yamashita (<xref rid="b11-ol-05-02-0463" ref-type="bibr">11</xref>) analyzed CEA mRNA expression in peripheral blood from 103 patients with NSCLC at the time of diagnosis, prior to surgery, and 2&#x02013;3 weeks later, following surgery. The results revealed that patients with high mRNA expression of CEA in the pre-operative blood samples had a poor survival rate when compared with those without CEA mRNA expression. Similarly, Yoon <italic>et a</italic>l (<xref rid="b12-ol-05-02-0463" ref-type="bibr">12</xref>) demonstrated that expression of CTCs in pulmonary peripheral blood was correlated with poor prognosis of the patient.</p><p>In this study, both CK19 and CD44v6 were used as markers to monitor the fluctuation in CTCs of patients. Whether micrometastasized cells in the blood of malignant tumor patients leads to the formation of metastatic foci depends on the invasiveness and adhesiveness of micrometastasized cells. CD44v6 is mainly expressed in a subset of adenocarcinomas and may be a useful marker for tumor screening. Studies demonstrated that the expression of adhesion molecule CD44v6 may reflect the invasiveness and adhesiveness of malignant tumor cells (<xref rid="b13-ol-05-02-0463" ref-type="bibr">13</xref>,<xref rid="b14-ol-05-02-0463" ref-type="bibr">14</xref>). Thus, the expression of CD44v6 in pulmonary venous blood was detected in this study, and the results revealed that the level of CD44v6 was closer to the experimental expectation than that of CK19. The expression of CD44v6 may be a good indicator of CTCs. However, this requires further investigation.</p><p>Our results suggested that ligation of the PV should be performed first during lobectomy. It was demonstrated that surgical manipulation itself may stimulate the occurrence of blood micrometastasis. Thus, ligation of the PV first during surgery may help to prevent blood micrometastasis. To clarify the clinical significance of different sequences of pulmonary vessel interruption, a prospective study with randomized selection of the method for each patient and with long-term follow-up should be conducted.</p></sec></body><back><ack><p>This study was supported by the Natural Science Foundation of Shandong (ZR2010HM067, ZR2011HM077) and the Provincial Science and Technology Foundation of Shandong (2011GGH21819).</p></ack><ref-list><title>References</title><ref id="b1-ol-05-02-0463"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kurusu</surname><given-names>Y</given-names></name><name><surname>Yamashita</surname><given-names>J</given-names></name><name><surname>Hayashi</surname><given-names>N</given-names></name><name><surname>Mita</surname><given-names>S</given-names></name><name><surname>Fujino</surname><given-names>N</given-names></name><name><surname>Ogawa</surname><given-names>M</given-names></name></person-group><article-title>The sequence of vessel ligation affects tumor release into the circulation</article-title><source>J Thorac Cardiovasc Surg</source><volume>116</volume><fpage>107</fpage><lpage>113</lpage><year>1998</year><pub-id pub-id-type="pmid">9671904</pub-id></element-citation></ref><ref id="b2-ol-05-02-0463"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Refaely</surname><given-names>Y</given-names></name><name><surname>Sadetzki</surname><given-names>S</given-names></name><name><surname>Chetrit</surname><given-names>A</given-names></name><name><surname>Simansky</surname><given-names>DA</given-names></name><name><surname>Paley</surname><given-names>M</given-names></name><name><surname>Modan</surname><given-names>B</given-names></name><name><surname>Yellin</surname><given-names>A</given-names></name></person-group><article-title>The sequence of vessel interruption during lobectomy for non-small cell lung cancer: is it indeed important?</article-title><source>J Thorac Cardiovasc Surg</source><volume>125</volume><fpage>1313</fpage><lpage>1320</lpage><year>2003</year><pub-id pub-id-type="pmid">12830050</pub-id></element-citation></ref><ref id="b3-ol-05-02-0463"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Okumura</surname><given-names>Y</given-names></name><name><surname>Tanaka</surname><given-names>F</given-names></name><name><surname>Yoneda</surname><given-names>K</given-names></name><name><surname>Hashimoto</surname><given-names>M</given-names></name><name><surname>Takuwa</surname><given-names>T</given-names></name><name><surname>Kondo</surname><given-names>N</given-names></name><name><surname>Hasegawa</surname><given-names>S</given-names></name></person-group><article-title>Circulating tumor cells in pulmonary venous blood of primary lung cancer patients</article-title><source>Ann Thorac Surg</source><volume>87</volume><fpage>1669</fpage><lpage>1675</lpage><year>2009</year><pub-id pub-id-type="pmid">19463575</pub-id></element-citation></ref><ref id="b4-ol-05-02-0463"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peck</surname><given-names>K</given-names></name><name><surname>Sher</surname><given-names>YP</given-names></name><name><surname>Shih</surname><given-names>JY</given-names></name><name><surname>Roffler</surname><given-names>SR</given-names></name><name><surname>Wu</surname><given-names>CW</given-names></name><name><surname>Yang</surname><given-names>PC</given-names></name></person-group><article-title>Detection and quantitation of circulating cancer cells in the peripheral blood of lung cancer patients</article-title><source>Cancer Res</source><volume>58</volume><fpage>2761</fpage><lpage>2765</lpage><year>1998</year><pub-id pub-id-type="pmid">9661888</pub-id></element-citation></ref><ref id="b5-ol-05-02-0463"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Turnbull</surname><given-names>RB</given-names><suffix>Jr</suffix></name><name><surname>Kyle</surname><given-names>K</given-names></name><name><surname>Watson</surname><given-names>FR</given-names></name><name><surname>Watson</surname><given-names>FR</given-names></name><name><surname>Spratt</surname><given-names>J</given-names></name></person-group><article-title>Cancer of the colon: the influence of the no-touch isolation technic on survival rates</article-title><source>Ann Surg</source><volume>166</volume><fpage>420</fpage><lpage>427</lpage><year>1967</year><pub-id pub-id-type="pmid">6039601</pub-id></element-citation></ref><ref id="b6-ol-05-02-0463"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hayashi</surname><given-names>N</given-names></name><name><surname>Egami</surname><given-names>H</given-names></name><name><surname>Kai</surname><given-names>M</given-names></name><name><surname>Kurusu</surname><given-names>Y</given-names></name><name><surname>Takano</surname><given-names>S</given-names></name><name><surname>Ogawa</surname><given-names>M</given-names></name></person-group><article-title>No-touch isolation technique reduces intraoperative shedding of tumor cells into the portal vein during resection of colorectal cancer</article-title><source>Surgery</source><volume>125</volume><fpage>369</fpage><lpage>374</lpage><year>1999</year><pub-id pub-id-type="pmid">10216526</pub-id></element-citation></ref><ref id="b7-ol-05-02-0463"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ge</surname><given-names>MJ</given-names></name><name><surname>Shi</surname><given-names>D</given-names></name><name><surname>Wu</surname><given-names>QC</given-names></name><name><surname>Wang</surname><given-names>M</given-names></name><name><surname>Li</surname><given-names>LB</given-names></name></person-group><article-title>Observation of circulating tumour cells in patients with non-small cell lung cancer by real-time fluorescent quantitative reverse transcriptasepolymerase chain reaction in perioperative period</article-title><source>J Cancer Res Clin Oncol</source><volume>132</volume><fpage>248</fpage><lpage>256</lpage><year>2006</year><pub-id pub-id-type="pmid">16320073</pub-id></element-citation></ref><ref id="b8-ol-05-02-0463"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yamashita</surname><given-names>JI</given-names></name><name><surname>Kurusu</surname><given-names>Y</given-names></name><name><surname>Fujino</surname><given-names>N</given-names></name><name><surname>Saisyoji</surname><given-names>T</given-names></name><name><surname>Ogawa</surname><given-names>M</given-names></name></person-group><article-title>Detection of circulating tumor cells in patients with non-small cell lung cancer undergoing lobectomy by video-assisted thoracic surgery: a potential hazard for intraoperative hematogenous tumor cell dissemination</article-title><source>J Thorac Cardiovasc Surg</source><volume>119</volume><fpage>899</fpage><lpage>905</lpage><year>2000</year><pub-id pub-id-type="pmid">10788810</pub-id></element-citation></ref><ref id="b9-ol-05-02-0463"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sawabata</surname><given-names>N</given-names></name><name><surname>Okumura</surname><given-names>M</given-names></name><name><surname>Utsumi</surname><given-names>T</given-names></name><name><surname>Inoue</surname><given-names>M</given-names></name><name><surname>Shiono</surname><given-names>H</given-names></name><name><surname>Minami</surname><given-names>M</given-names></name><name><surname>Nishida</surname><given-names>T</given-names></name><name><surname>Sawa</surname><given-names>Y</given-names></name></person-group><article-title>Circulating tumor cells in peripheral blood caused by surgical manipulation of non-small-cell lung cancer: pilot study using an immunocytology method</article-title><source>Gen Thorac Cardiovasc Surg</source><volume>55</volume><fpage>189</fpage><lpage>192</lpage><year>2007</year><pub-id pub-id-type="pmid">17554991</pub-id></element-citation></ref><ref id="b10-ol-05-02-0463"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tanaka</surname><given-names>F</given-names></name><name><surname>Yoneda</surname><given-names>K</given-names></name><name><surname>Kondo</surname><given-names>N</given-names></name><name><surname>Hashimoto</surname><given-names>M</given-names></name><name><surname>Takuwa</surname><given-names>T</given-names></name><name><surname>Matsumoto</surname><given-names>S</given-names></name><name><surname>Okumura</surname><given-names>Y</given-names></name><name><surname>Rahman</surname><given-names>S</given-names></name><name><surname>Tsubota</surname><given-names>N</given-names></name><name><surname>Tsujimura</surname><given-names>T</given-names></name><name><surname>Kuribayashi</surname><given-names>K</given-names></name><etal/></person-group><article-title>Circulating tumor cell as a diagnostic marker in primary lung cancer</article-title><source>Clin Cancer Res</source><volume>15</volume><fpage>6980</fpage><lpage>6986</lpage><year>2009</year><pub-id pub-id-type="pmid">19887487</pub-id></element-citation></ref><ref id="b11-ol-05-02-0463"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yamashita</surname><given-names>J</given-names></name><name><surname>Matsuo</surname><given-names>A</given-names></name><name><surname>Kurusu</surname><given-names>Y</given-names></name><name><surname>Saishoji</surname><given-names>T</given-names></name><name><surname>Hayashi</surname><given-names>N</given-names></name><name><surname>Ogawa</surname><given-names>M</given-names></name></person-group><article-title>Preoperative evidence of circulating tumor cells by means of reverse transcriptase-polymerase chain reaction for carcinoembryonic antigen messenger RNA is an independent predictor of survival in non-small cell lung cancer: a prospective study</article-title><source>J Thorac Cardiovasc Surg</source><volume>124</volume><fpage>299</fpage><lpage>305</lpage><year>2002</year><pub-id pub-id-type="pmid">12167790</pub-id></element-citation></ref><ref id="b12-ol-05-02-0463"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yoon</surname><given-names>SO</given-names></name><name><surname>Kim</surname><given-names>YT</given-names></name><name><surname>Jung</surname><given-names>KC</given-names></name><name><surname>Jeon</surname><given-names>YK</given-names></name><name><surname>Kim</surname><given-names>BH</given-names></name><name><surname>Kim</surname><given-names>CW</given-names></name></person-group><article-title>TTF-1 mRNA-positive circulating tumor cells in the peripheral blood predict poor prognosis in surgically resected non-small cell lung cancer patients</article-title><source>Lung Cancer</source><volume>71</volume><fpage>209</fpage><lpage>216</lpage><year>2011</year><pub-id pub-id-type="pmid">20471712</pub-id></element-citation></ref><ref id="b13-ol-05-02-0463"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Amirghofran</surname><given-names>Z</given-names></name><name><surname>Jalali</surname><given-names>SA</given-names></name><name><surname>Hosseini</surname><given-names>SV</given-names></name><name><surname>Vasei</surname><given-names>M</given-names></name><name><surname>Sabayan</surname><given-names>B</given-names></name><name><surname>Ghaderi</surname><given-names>A</given-names></name></person-group><article-title>Evaluation of CD44 and CD44v6 in colorectal carcinoma patients: soluble forms in relation to tumor tissue expression and metastasis</article-title><source>J Gastrointest Cancer</source><volume>39</volume><fpage>73</fpage><lpage>78</lpage><year>2008</year><pub-id pub-id-type="pmid">19333790</pub-id></element-citation></ref><ref id="b14-ol-05-02-0463"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Huang</surname><given-names>K</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Lin</surname><given-names>X</given-names></name><name><surname>Zhu</surname><given-names>Z</given-names></name><name><surname>Wu</surname><given-names>Y</given-names></name></person-group><article-title>Generation of a stable anti-human CD44v6 scFv and analysis of its cancer-targeting ability in vitro</article-title><source>Cancer Immunol Immunother</source><volume>59</volume><fpage>933</fpage><lpage>942</lpage><year>2010</year><pub-id pub-id-type="pmid">20224978</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="f1-ol-05-02-0463" orientation="portrait" position="float"><label>Figure 1.</label><caption><p>Fluorescent quantitative RT-PCR amplification curves of &#x003b2;-actin. The graph of the increment of fluorescence reporter signal (DRn) versus cycle number during PCR.</p></caption><graphic xlink:href="OL-05-02-0463-g00"/></fig><fig id="f2-ol-05-02-0463" orientation="portrait" position="float"><label>Figure 2.</label><caption><p>Fluorescent quantitative RT-PCR amplification curves of CD44v6. The graph of the increment of fluorescence reporter signal (DRn) versus cycle number during PCR.</p></caption><graphic xlink:href="OL-05-02-0463-g01"/></fig><fig id="f3-ol-05-02-0463" orientation="portrait" position="float"><label>Figure 3.</label><caption><p>Fluorescent quantitative RT-PCR amplification curves of CK19. The graph of the increment of fluorescence reporter signal (DRn) versus cycle number during PCR.</p></caption><graphic xlink:href="OL-05-02-0463-g02"/></fig><table-wrap id="t1-ol-05-02-0463" orientation="portrait" position="float"><label>Table I.</label><caption><p>Differences in mRNA expression between CD44v6 and CK19 in pulmonary venous blood of NSCLC groups and those in the control group.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="middle" rowspan="1" colspan="1">Group</th><th align="center" valign="middle" rowspan="1" colspan="1">Number of cases</th><th align="center" valign="middle" rowspan="1" colspan="1">CD44V6</th><th align="center" valign="middle" rowspan="1" colspan="1">CK19</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">NSCLC</td><td align="center" valign="top" rowspan="1" colspan="1">30</td><td align="center" valign="top" rowspan="1" colspan="1">7.83&#x000b1;1.70</td><td align="center" valign="top" rowspan="1" colspan="1">10.76&#x000b1;2.74</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Control</td><td align="center" valign="top" rowspan="1" colspan="1">10</td><td align="center" valign="top" rowspan="1" colspan="1">9.17&#x000b1;1.04</td><td align="center" valign="top" rowspan="1" colspan="1">12.76&#x000b1;2.36</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">P-value</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">0.006</td><td align="center" valign="top" rowspan="1" colspan="1">0.039</td></tr></tbody></table><table-wrap-foot><fn id="tfn1-ol-05-02-0463"><p>NSCLC; non-small cell lung cancer.</p></fn></table-wrap-foot></table-wrap><table-wrap id="t2-ol-05-02-0463" orientation="portrait" position="float"><label>Table II.</label><caption><p>Patient characteristics and the expression of CD44v6 and CK19.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom" rowspan="1" colspan="1"/><th align="center" valign="bottom" rowspan="1" colspan="1"/><th colspan="4" align="center" valign="bottom" rowspan="1">Early period
<hr/></th><th colspan="4" align="center" valign="bottom" rowspan="1">Late period
<hr/></th></tr><tr><th align="left" valign="bottom" rowspan="1" colspan="1">Patient characteristics</th><th align="center" valign="bottom" rowspan="1" colspan="1">No.</th><th align="center" valign="bottom" rowspan="1" colspan="1">CD44v6</th><th align="center" valign="bottom" rowspan="1" colspan="1">P-value</th><th align="center" valign="bottom" rowspan="1" colspan="1">CK19</th><th align="center" valign="bottom" rowspan="1" colspan="1">P-value</th><th align="center" valign="bottom" rowspan="1" colspan="1">CD44v6</th><th align="center" valign="bottom" rowspan="1" colspan="1">P-value</th><th align="center" valign="bottom" rowspan="1" colspan="1">CK19</th><th align="center" valign="bottom" rowspan="1" colspan="1">P-value</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">Gender</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">0.875</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">0.266</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">0.552</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">0.271</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;Male</td><td align="center" valign="top" rowspan="1" colspan="1">14</td><td align="center" valign="top" rowspan="1" colspan="1">7.78&#x000b1;2.13</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">11.43&#x000b1;3.04</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">7.08&#x000b1;2.46</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">10.41&#x000b1;3.52</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;Female</td><td align="center" valign="top" rowspan="1" colspan="1">16</td><td align="center" valign="top" rowspan="1" colspan="1">7.89&#x000b1;1.93</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">10.17&#x000b1;3.02</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">6.57&#x000b1;2.16</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">8.90&#x000b1;3.81</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Smoking</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">0.890</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">0.293</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">0.241</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">0.133</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;Yes</td><td align="center" valign="top" rowspan="1" colspan="1">20</td><td align="center" valign="top" rowspan="1" colspan="1">7.86&#x000b1;2.28</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">9.83&#x000b1;3.56</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">6.41&#x000b1;1.97</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">8.88&#x000b1;3.66</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;Non</td><td align="center" valign="top" rowspan="1" colspan="1">10</td><td align="center" valign="top" rowspan="1" colspan="1">7.77&#x000b1;1.40</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">11.22&#x000b1;2.73</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">7.61&#x000b1;2.77</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">11.04&#x000b1;3.49</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Histology</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">0.652</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">0.377</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">0.008</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">0.242</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;Squamous cell carcinoma</td><td align="center" valign="top" rowspan="1" colspan="1">14</td><td align="center" valign="top" rowspan="1" colspan="1">8.01&#x000b1;2.26</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">10.29&#x000b1;2.46</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">7.95&#x000b1;1.81</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">8.85&#x000b1;3.60</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;Adenocarcinoma</td><td align="center" valign="top" rowspan="1" colspan="1">16</td><td align="center" valign="top" rowspan="1" colspan="1">7.67&#x000b1;1.82</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">11.29&#x000b1;3.62</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">5.81&#x000b1;2.23</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">10.46&#x000b1;3.75</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Site of primary tumor</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">0.965</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">0.142</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">0.082</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">0.133</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;Hilar</td><td align="center" valign="top" rowspan="1" colspan="1">11</td><td align="center" valign="top" rowspan="1" colspan="1">7.85&#x000b1;2.02</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">9.67&#x000b1;3.24</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">5.86&#x000b1;2.14</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">8.26&#x000b1;3.96</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;Peripheral</td><td align="center" valign="top" rowspan="1" colspan="1">19</td><td align="center" valign="top" rowspan="1" colspan="1">7.82&#x000b1;2.05</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">11.38&#x000b1;2.82</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">7.36&#x000b1;2.24</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">10.38&#x000b1;3.40</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Pathological stage</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">0.331</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">0.496</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">0.059</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">0.159</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;I</td><td align="center" valign="top" rowspan="1" colspan="1">9</td><td align="center" valign="top" rowspan="1" colspan="1">8.47&#x000b1;2.06</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">11.51&#x000b1;3.25</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">7.96&#x000b1;1.43</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">10.59&#x000b1;3.67</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;II</td><td align="center" valign="top" rowspan="1" colspan="1">13</td><td align="center" valign="top" rowspan="1" colspan="1">7.89&#x000b1;2.05</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">10.00&#x000b1;2.92</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">6.91&#x000b1;2.37</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">10.23&#x000b1;2.93</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;IIIA</td><td align="center" valign="top" rowspan="1" colspan="1">8</td><td align="center" valign="top" rowspan="1" colspan="1">7.01&#x000b1;1.82</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">11.14&#x000b1;3.12</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">5.36&#x000b1;2.17</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">7.47&#x000b1;4.38</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr></tbody></table></table-wrap><table-wrap id="t3-ol-05-02-0463" orientation="portrait" position="float"><label>Table III.</label><caption><p>Effects of different sequences of ligation during surgery on the mRNA expression of CD44v6 and CK19.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom" rowspan="1" colspan="1"/><th align="center" valign="bottom" rowspan="1" colspan="1"/><th colspan="3" align="center" valign="bottom" rowspan="1">CD44v6
<hr/></th><th colspan="3" align="center" valign="bottom" rowspan="1">CK19
<hr/></th></tr><tr><th align="left" valign="bottom" rowspan="1" colspan="1">Group</th><th align="center" valign="bottom" rowspan="1" colspan="1">Number of cases</th><th align="center" valign="bottom" rowspan="1" colspan="1">Early period</th><th align="center" valign="bottom" rowspan="1" colspan="1">Late period</th><th align="center" valign="bottom" rowspan="1" colspan="1">P-value</th><th align="center" valign="bottom" rowspan="1" colspan="1">Early period</th><th align="center" valign="bottom" rowspan="1" colspan="1">Late period</th><th align="center" valign="bottom" rowspan="1" colspan="1">P-value</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">PA-first</td><td align="center" valign="top" rowspan="1" colspan="1">15</td><td align="center" valign="top" rowspan="1" colspan="1">7.92&#x000b1;1.97</td><td align="center" valign="top" rowspan="1" colspan="1">5.67&#x000b1;2.11</td><td align="center" valign="top" rowspan="1" colspan="1">0.008</td><td align="center" valign="top" rowspan="1" colspan="1">11.21&#x000b1;3.14</td><td align="center" valign="top" rowspan="1" colspan="1">8.60&#x000b1;4.02</td><td align="center" valign="top" rowspan="1" colspan="1">0.050</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">PV-first</td><td align="center" valign="top" rowspan="1" colspan="1">15</td><td align="center" valign="top" rowspan="1" colspan="1">7.95&#x000b1;1.91</td><td align="center" valign="top" rowspan="1" colspan="1">7.74&#x000b1;2.10</td><td align="center" valign="top" rowspan="1" colspan="1">0.558</td><td align="center" valign="top" rowspan="1" colspan="1">10.60&#x000b1;3.15</td><td align="center" valign="top" rowspan="1" colspan="1">10.30&#x000b1;2.98</td><td align="center" valign="top" rowspan="1" colspan="1">0.532</td></tr></tbody></table><table-wrap-foot><fn id="tfn2-ol-05-02-0463"><p>PA, pulmonary artery; PV, pulmonary vein.</p></fn></table-wrap-foot></table-wrap></floats-group></article>